Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement
Covered in this story
What has happened since
- CMS Energy is up 10.5% since this was published, 21 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $CMS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on CMS Energy →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.